Published online Aug 8, 2016. doi: 10.5409/wjcp.v5.i3.281
Peer-review started: March 22, 2016
First decision: April 20, 2016
Revised: May 3, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: August 8, 2016
Processing time: 141 Days and 19.2 Hours
There are several different types of drug delivery interfaces available on the market. Using the right interface for aerosol drug delivery to children is essential for effective inhalation therapy. However, clinicians usually focus on selecting the right drug-device combination and often overlook the importance of interface selection that lead to suboptimal drug delivery and therapeutic response in neonates and pediatrics. Therefore, it is necessary to critically assess each interface and understand its advantage and disadvantages in aerosol drug delivery to this patient population. The purpose of this paper is to provide a critical assessment of drug delivery interfaces used for the treatment of children with pulmonary diseases by emphasizing advantages and problems associated with their use during inhalation therapy.
Core tip: Many interfaces exist for aerosol drug delivery to spontaneously breathing children and inhalation therapy with different interfaces has become an important topic of interest among clinicians. However, clinicians usually focus on selecting the right drug-device combination and often overlook the importance of interface selection that lead to suboptimal drug delivery and therapeutic response in neonates and pediatrics. This paper provides a critical assessment of drug delivery interfaces used for the treatment of children with pulmonary diseases by emphasizing advantages and problems associated with their use during inhalation therapy.